Evidence map›Paper›PMID 42140186›Full record

ArticleStructure (London, England : 1993)2026

Structural basis for the subtype-selective activation of K

Alena Ramanishka, Joshua A Nasburg, Yang Xu, Xinyi Ma, Reza Mehvar, Meng Cui, Young-Woo Nam, Heike Wulff, Miao Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Structure (London, England : 1993), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alena RamanishkaDepartment of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, AZ 85004, USA; Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA.
Joshua A NasburgDepartment of Pharmacology, School of Medicine, University of California, Davis, Davis, CA 95616, USA.
Yang XuDivision of CryoEM and Bioimaging, Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, Stanford University, Menlo Park, CA 94025, USA.
Xinyi MaDepartment of Pharmaceutical Sciences and the Center for Drug Discovery, School of Pharmacy and Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, MA 02115, USA.
Reza MehvarDepartment of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA.
Meng CuiDepartment of Pharmaceutical Sciences and the Center for Drug Discovery, School of Pharmacy and Pharmaceutical Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, MA 02115, USA.
Young-Woo NamDepartment of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, AZ 85004, USA; Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA. Electronic address: ywnam@arizona.edu.
Heike WulffDepartment of Pharmacology, School of Medicine, University of California, Davis, Davis, CA 95616, USA. Electronic address: hwulff@health.ucdavis.edu.
Miao ZhangDepartment of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, AZ 85004, USA; Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Irvine, CA 92618, USA. Electronic address: miaozhangphd@arizona.edu.

Funding

The Stanford-SLAC CryoEM Center supplementU24GM129541 · NIGMS · STANFORD UNIVERSITY · PI CHIU, WAH, HEDMAN, BRITT · 2018 to 2023
$54.8M
Molecular mechanism for pharmacological activation of KCa2 channelsR01NS145389 · NINDS · UNIVERSITY OF ARIZONA · PI HEIKE WULFF, Miao Zhang · 2025 to 2026
$1.2M
Channelopathy of KCa2.3 and Zimmermann-Laband syndromeR15NS130420 · NINDS · CHAPMAN UNIVERSITY · PI ZHANG, MIAO · 2024 to 2024
$434k
NIGMS NIH HHS U24 GM129541NINDS NIH HHS R01 NS145389NINDS NIH HHS R15 NS130420
6 · The paper itself

Abstract

The intermediate-conductance (K

Indexed as

BenzothiazolesIntermediate-Conductance Calcium-Activated Potassium ChannelsSmall-Conductance Calcium-Activated Potassium ChannelsAllosteric RegulationAnimalsBinding SitesCalmodulinCryoelectron MicroscopyHumansModels, MolecularProtein BindingBenzothiazolesCalmodulinIntermediate-Conductance Calcium-Activated Potassium ChannelsKCNN2 protein, humanSmall-Conductance Calcium-Activated Potassium Channelsactivatorcryo-EMK(Ca)2.2K(Ca)3.1SKA-111SKA-31

Identifiers

PMID42140186
PMCPMC13377835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.